You have 1 action to finish to complete your account. Customize your experience by selecting your interests on the Personalization page
No matches

128 search results for: type 2 inflammation

<b>Type</b> <b>2</b> <b>Inflammation</b> Mediates Severe Asthma in Pediatric Patients
expert video

Type 2 Inflammation Mediates Severe Asthma in Pediatric Patients

Pulmonology
Dr. Leonard Bacharier discusses how type 2 inflammation underlies the pathophysiology of pediatric severe asthma and contributes to burden.
View more
<b>Type</b> <b>2</b> <b>Inflammation</b> Is a Significant Driver of Pediatric Severe Asthma
Infographic

Type 2 Inflammation Is a Significant Driver of Pediatric Severe Asthma

Pulmonology
Learn about the role of type 2 inflammation in the burden and pathophysiology of severe asthma in pediatric patients
View more
Managing <b>Type</b> <b>2</b> Inflammatory Diseases: Multidisciplinary Frame of Mind
expert video

Managing Type 2 Inflammatory Diseases: Multidisciplinary Frame of Mind

Type 2 Inflammation
Drs. Bob Geng and Lawrence Eichenfield highlight a multidisciplinary team approach to patient-centered care in diseases with type 2 inflammation
View more
Itch: The Common Thread in Dermatological <b>Type</b> <b>2</b> <b>Inflammation</b> (AD, PN, and CSU)​
expert video

Itch: The Common Thread in Dermatological Type 2 Inflammation (AD, PN, and CSU)​

Dermatology
A review of the shared and unique neuroimmune mechanisms in the generation of itch across AD, PN, and CSU.
View more
Itch: The Common Thread in Dermatological <b>Type</b> <b>2</b> <b>Inflammation</b> (AD, PN, and CSU)​ - Panel Discussion
expert video

Itch: The Common Thread in Dermatological Type 2 Inflammation (AD, PN, and CSU)​ - Panel Discussion

Dermatology
Panel discussion exploring how itch differs across AD, PN, and CSU, and how it affects pediatric patients with AD.
View more
The Impact of <b>Type</b> <b>2</b> <b>Inflammation</b> on the Neuroimmune Axis in AD
expert video

The Impact of Type 2 Inflammation on the Neuroimmune Axis in AD

Dermatology
Dr. Gil Yosipovitch discussed the interaction between type 2 inflammation and itch in AD, the role of type 2 inflammation on neuroarchitecture, and the role of type 2 cytokines in neuronal sensitization.
View more
FeNO: A Biomarker of <b>Type</b> <b>2</b> <b>Inflammation</b> in Pediatric Asthma Patients
Infographic

FeNO: A Biomarker of Type 2 Inflammation in Pediatric Asthma Patients

Pulmonology
Learn about the role of FeNO as a noninvasive test to identify type 2 inflammation in pediatric patients with asthma
View more
The Role of <b>Type</b> <b>2</b> <b>Inflammation</b> in Multiple Disease Trajectories
Infographic

The Role of Type 2 Inflammation in Multiple Disease Trajectories

Dermatology
How type 2 inflammation drives atopic dermatitis and underlies other atopic diseases across multiple disease trajectories including the atopic march.
View more
Potential Role of Type 2 Inflammation in the Pathogenesis of CSU
expert video

Potential Role of Type 2 Inflammation in the Pathogenesis of CSU

Dermatology
Join Professor Hide as he describes the potential role of Type 2 inflammation in the pathogenesis of CSU.
View more
A Triad of Interacting Mechanisms Driving the Pathophysiology of AD, Asthma, CRSwNP, and EoE
Infographic

A Triad of Interacting Mechanisms Driving the Pathophysiology of AD, Asthma, CRSwNP, and EoE

Type 2 Inflammation
Discover how barrier dysfunction, neuroimmune dysregulation, and type 2 inflammation contribute to the pathophysiology of various diseases
View more
IRS-ISIAN <b>2</b>0<b>2</b>4 | Targeting <b>Type</b> <b>2</b> <b>Inflammation</b>: Managing Smell Loss and Congestion in Patients With Recurrent CRSwNP
expert video

IRS-ISIAN 2024 | Targeting Type 2 Inflammation: Managing Smell Loss and Congestion in Patients With Recurrent CRSwNP

Rhinology
Prof. Joaquim Mullol reports on biologic improvements in sense of smell and nasal congestion in patients with and without a history of endoscopic sinus surgery.
View more

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi | Regeneron Logo

© 2025 Sanofi and Regeneron Pharmaceuticals, Inc.

All rights reserved.
MAT-GLB-2302957 v3.0 11/2023

All Rights Reserved.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: Costa RicaChange country/region